Tongxie Yaofang ameliorates IBS-D by targeting the gut microbiota-derived tryptophan metabolites and AhR signaling axis
Frontiers in Microbiology · 30.04.2026 · 17
DOI: 10.3389/fmicb.2026.1786701 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Microbiology, online erschienen am 30.04.2026. Verfasst von Xiangyu Xie und 10 weiteren Autor:innen. Beteiligte Einrichtung: The First Clinical School of Guangzhou University of Chinese Medicine, Guangzhou, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and aims Tongxie Yaofang (TXYF) is a classic prescription for IBS-D with liver depression and spleen deficiency, with its therapeutic mechanisms requiring further elucidation. This study investigated the modulatory effects of TXYF on the gut microbiota and microbiota-derived metabolism in an IBS-D rat model to elucidate the underlying mechanisms.
Methods
HPLC was employed to identify the main components of TXYF. An IBS-D rat model was replicated using a triple-factor approach that combined neonatal maternal separation, chronic restraint stress, and oral gavage of Sennae folium decoction. To elucidate the mechanisms underlying the effects of TXYF on IBS-D, the gut microbiota was assessed by 16S rRNA sequencing, and microbial metabolites were profiled via untargeted metabolomics. Furthermore, key regulatory factors were examined by immunohistochemistry (IHC), reverse transcription-quantitative polymerase chain reaction (RT-qPCR), and western blotting. Finally, fecal microbiota transplantation (FMT) was performed to validate the pathogenic role of the microbiota and the therapeutic potential of TXYF.
Results
TXYF significantly alleviated IBS-D symptoms in rats, including diarrhea and abdominal pain, and improved both depressive-like behavior and intestinal barrier function. Treatment with TXYF increased the abundance of Bifidobacterium in the gut microbiota and promoted the microbial-related metabolic conversion of tryptophan (TRP) to 5-hydroxyindoleacetic acid (5-HIAA), indole-3-acetic acid (IAA), tryptamine, 5-hydroxytryptamine (5-HT), and 2-oxindole. These metabolites activated the aryl hydrocarbon receptor (AhR) signaling pathway, thereby inhibiting MLC phosphorylation and decreasing MLCK expression, and ultimately restoring intestinal barrier function. Furthermore, the FMT experiment demonstrated that the microbiota from TXYF-treated rats significantly ameliorated IBS-D by activating the AhR signaling pathway.
Conclusion
TXYF may alleviate IBS-D symptoms and restore barrier function by increasing the abundance of Bifidobacterium , restoring tryptophan metabolism, and activating the AhR pathway.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The First Clinical School of Guangzhou University of Chinese Medicine, Guangzhou, China.
- The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
- Lingnan Research Center of Guangzhou University of Chinese Medicine, Guangzhou, China.
- Guangdong Clinical Research Academy of Chinese Medicine, Guangzhou, China.
- Zhongshan Hospital of Traditional Chinese Medicine, Zhongshan, China.
- Foshan Hospital of Traditional Chinese Medicine, Foshan, China.
Zitieren
APA
Xie, X., Yan, W., Gan, C., Xiong, W., Huang, Y., Lin, L., Lei, X., Ke, W., Chai, Y., Tang, H., & Zhu, H. (2026). Tongxie Yaofang ameliorates IBS-D by targeting the gut microbiota-derived tryptophan metabolites and AhR signaling axis. Frontiers in Microbiology, 17. https://doi.org/10.3389/fmicb.2026.1786701
Vancouver
Xie X, Yan W, Gan C, Xiong W, Huang Y, Lin L, et al. Tongxie Yaofang ameliorates IBS-D by targeting the gut microbiota-derived tryptophan metabolites and AhR signaling axis. Frontiers in Microbiology. 2026;17. doi:10.3389/fmicb.2026.1786701
BibTeX
@article{Xie2026,
author = {Xie, Xiangyu and Yan, Weixin and Gan, Chunli and Xiong, Wei and Huang, Yusheng and Lin, Lijun and Lei, Xiaochun and Ke, Wei and Chai, Yuna and Tang, Hongmei and Zhu, He},
title = {Tongxie Yaofang ameliorates IBS-D by targeting the gut microbiota-derived tryptophan metabolites and AhR signaling axis},
journal = {Frontiers in Microbiology},
year = {2026},
volume = {17},
doi = {10.3389/fmicb.2026.1786701}
}
EUVIMED